Lifestyle adjustments can help prevent UTIs. While not a proven cure, cranberry products and D-mannose supplements may help ...
Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.
Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...
The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for ...
2d
Verywell Health on MSNA New FDA-Approved Antibiotic May Help Women With Recurring UTIsIf you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...
The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract ...
7d
Everyday Health on MSNFDA Approves the First New UTI Antibiotic in Nearly 30 YearsThis antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...
8d
Interesting Engineering on MSNNew hope for UTI patients as FDA approves first-of-its-kind antibiotic in 30 yearsThe U.S. Food and Drug Administration (FDA) has approved a new class of antibiotics for treating uncomplicated urinary tract ...
The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be available in the second half of 2025.
The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...
The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be available in the second half of 2025. Blujepa is approved to treat females 12 and older with uncomplicated ...
Gepotidacin is an oral ... and vulvovaginal candidiasis. “The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women,” said Tony Wood, Chief Scientific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results